Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.

Key facts

Study ID
NCT02738775
Run by
TG Therapeutics, Inc.
People needed
49
Starts
2016-05-27
Expected to finish
2018-08-13
Last updated by the study team
2021-07-15

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.